EP
ABVX

Eversept Partners’s Abivax ABVX Stock Holding History

Eversept Partners’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$122M Sell
913,880
-20,543
-2% -$2.32M 6.32% 2
2026
Q1 		$104M Buy
934,423
+276,589
+42% +$32.7M 5.49% 3
2025
Q4 		$88.7M Buy
657,834
+231,335
+54% +$25.2M 4.47% 5
2025
Q3 		$36.2M Buy
+426,499
New +$26.1M 2.5% 12

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $3.35B AUM 55.08% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Eversept Partners's ABVX Position: Q2 2026 in Review

Eversept Partners reduced its Abivax (ABVX) stake by 2.2% in Q2 2026, selling an estimated $2.32M and leaving 913,880 shares worth $122M. The position accounts for 6.32% of the portfolio, ranked #2.

Eversept Partners first reported a position in ABVX in Q3 2025 and has held it in 4 quarters since. 302 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

  • Eversept Partners held 913,880 shares of Abivax worth $122M as of Q2 2026.
  • Eversept Partners sold 20,543 Abivax shares in Q2 2026, an estimated $2.32M.
  • Abivax made up 6.32% of Eversept Partners's portfolio in Q2 2026, its #2 holding.
  • Eversept Partners first reported a position in Abivax in Q3 2025 and has held it in 4 quarters since.
  • 302 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on Eversept Partners's 13F filing for Q2 2026, filed 14 Aug 2026.